longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

IX Biopharma

42C

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
Share your thoughts

What's on your mind?

0 / 2,000
  • T
    TheInvestingIguanaAJBURate Of ReturnJul 21 at 08:35 AM

    CSE Global Jumps 6% Heading Into the Close | Daily Pulse | 🦖

    🔍 The Angle

    CSE Global is up almost 6% on a day when the index barely moves, and IX Biopharma is swinging close to 8% on tiny volume. Underneath a quiet tape, we have real money shifting in CSE, YZJ, UMS, while names like HS Optimus and Prospera Global print wild percentages at fractions of a cent that can mislead anyone watching only the gainers list. The tension I am watching is simple, which of today’s big moves are genuine signals for your income, and which are just statistical noise.

    💰 What It Means For You

    If you rely on CPF, SRS, or REIT dividends, a 6% spike in a name you hold can feel like a win, but without checking volume, price level, and the underlying business news, it might be as empty as a one trade move at S$0.01. Today is a textbook reminder that big percentage moves at penny levels rarely clear any sensible 4.7% yield hurdle or 3.2% forensic floor, they just make the screen light up. I want you to separate the CSE or CICT type moves, tied to real strategic reviews and Paragon capex, from the HS Optimus type moves, where the number is loud but the story is thin.

    📺 YouTube:  https://youtu.be/aZVUpayZ4q4

    📩 Substack: https://investingiguana.com/p/cse-global-jumps-6-heading-into-the

    - YouTube

    - YouTube

    YouTube 上盡享你喜愛的影片和音樂、上載原創內容,並與親友和世界各地的人分享。

    youtu.be
    CSE GLOBAL JUMPS6%/ THEDAILY HEADING INTO THE CLOSE PULSE PODCAST ODC A S lggy t
  • F
    FundamentalistRate Of ReturnApr 22 at 05:07 AM

    My Opinion on IX Biopharma (42C.SG)

    Based on a comprehensive analysis of the provided data, the future of IX Biopharma (42C.SG) $IX Biopharma(42C.SG) presents a high-risk, binary outcome. The company’s path is defined by a promising lon...

  • O
    Old oneFeb 16 at 12:20 PM

    iX Biopharma has announced a non-binding term sheet with Orion Specialty Labs to form a joint venture in the U.S. iX will own 75 percent of the venture while Orion takes 25 percent and covers the capital costs. The goal is to use Orion’s existing FDA-licensed facilities to bring iX’s WaferiX technology to market faster, with pilot production aimed for the second half of 2026. The deal is not yet final, and there’s no expected immediate financial impact for iX.���������